WeVote
Log In

Bill

Bill

H 2203

An Act establishing a pilot program for access to regulated psilocybin

194th Legislature (2025-2026) Introduced by Marjorie Decker and 1 co-sponsor

Massachusetts establishes a pilot program enabling regulated psilocybin access for therapeutic use while navigating federal drug scheduling conflicts and implementation uncertainties.

Reporting date extended to Thursday, December 31, 2026
0
WeVote Research Nonpartisan
Bill Summary · H 2203

Legislative bill overview

H 2203 establishes a pilot program in Massachusetts allowing regulated access to psilocybin (a psychoactive compound in certain mushrooms) under controlled conditions. The bill creates a framework for therapeutic use, likely under medical supervision, while maintaining regulatory oversight to ensure safety and proper administration.

Why is this important

Psilocybin has shown promising results in clinical research for treating treatment-resistant depression, PTSD, and end-of-life anxiety. This pilot program could provide Massachusetts residents access to an emerging therapeutic option while generating data on efficacy, safety protocols, and implementation models that could inform policy nationally.

Potential points of contention

  • Federal legal status: Psilocybin remains a Schedule I controlled substance federally, creating tension between state authorization and federal law that could complicate program implementation
  • Patient access and equity: Questions about who qualifies, cost, insurance coverage, and whether the program adequately serves low-income or historically marginalized communities
  • Regulatory uncertainty: Lack of established standards for dosing, provider training, screening protocols, and long-term outcome tracking in a newly regulated therapeutic context
  • Public perception and safety concerns: Opposition from those skeptical of psychedelic drugs, concerns about misuse potential, and debates over adequate safeguards

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.